This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: Data were obtained from a German multicenter, single-arm, open-label study of patients with RRMS treated with fingolimod, and findings were validated in an independent Swedish national pharmacovigilance study.
Results: Four hundred eighteen patients with RRMS from Germany and 438 patients from Sweden were included. A nadir ≤0.2 × 109 lymphocytes/L was reached in 15% (95% confidence interval [CI] 12%–17%) of all 856 patients. Patients with lower starting lymphocyte counts (below 1.6 × 109/L) and patients with BMI lower than 18.5 kg/m2 (women only) were at higher risk of developing lymphopenia with values ≤0.2 × 109/L in the combined analysis, increasing the risk in these subgroups to 26% (95% CI 20%–31%) or 46% (95% CI 23%–71%), respectively. In the German cohort, infection rates were similar in patients who developed severe lymphopenia and those who did not.
Conclusions: Our findings suggest that patients with low baseline lymphocyte counts and underweight women in which fingolimod treatment will be initiated should possibly be monitored more closely.
GLOSSARY
- BMI=
- body mass index;
- CI=
- confidence interval;
- MS=
- multiple sclerosis;
- OR=
- odds ratio;
- RRMS=
- relapsing-remitting multiple sclerosis
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received April 4, 2014.
- Accepted in final form September 3, 2014.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Lymphocyte counts and infection rates
Lymphocyte recovery after fingolimod discontinuation in patients with MS
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS